396 related articles for article (PubMed ID: 31869412)
1. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP.
Baccarani M; Abruzzese E; Accurso V; Albano F; Annunziata M; Barulli S; Beltrami G; Bergamaschi M; Binotto G; Bocchia M; Caocci G; Capodanno I; Cavazzini F; Cedrone M; Cerrano M; Crugnola M; D'Adda M; Elena C; Fava C; Fazi P; Fozza C; Galimberti S; Giai V; Gozzini A; Gugliotta G; Iurlo A; La Barba G; Levato L; Lucchesi A; Luciano L; Lunghi F; Lunghi M; Malagola M; Marasca R; Martino B; Melpignano A; Miggiano MC; Montefusco E; Musolino C; Palmieri F; Pregno P; Rapezzi D; Rege-Cambrin G; Rupoli S; Salvucci M; Sancetta R; Sica S; Spadano R; Stagno F; Tiribelli M; Tomassetti S; Trabacchi E; Bonifacio M; Breccia M; Castagnetti F; Pane F; Russo D; Saglio G; Soverini S; Vigneri P; Rosti G
Blood Adv; 2019 Dec; 3(24):4280-4290. PubMed ID: 31869412
[TBL] [Abstract][Full Text] [Related]
2. WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors.
Haznedaroğlu İC; Kuzu I; İlhan O
Turk J Haematol; 2020 Feb; 37(1):42-47. PubMed ID: 31612694
[TBL] [Abstract][Full Text] [Related]
3. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.
Shanmuganathan N; Pagani IS; Ross DM; Park S; Yong ASM; Braley JA; Altamura HK; Hiwase DK; Yeung DT; Kim DW; Branford S; Hughes TP
Blood; 2021 Mar; 137(9):1196-1207. PubMed ID: 32871588
[TBL] [Abstract][Full Text] [Related]
4. Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia.
Caldemeyer L; Akard LP
Leuk Lymphoma; 2016 Dec; 57(12):2739-2751. PubMed ID: 27562641
[TBL] [Abstract][Full Text] [Related]
5. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
Cayssials E; Torregrosa-Diaz J; Gallego-Hernanz P; Tartarin F; Systchenko T; Maillard N; Desmier D; Machet A; Fleck E; Corby A; Motard C; Denis G; Herbelin A; Gombert JM; Roy L; Ragot S; Leleu X; Guilhot F; Chomel JC
Cancer; 2020 Aug; 126(15):3438-3447. PubMed ID: 32459375
[TBL] [Abstract][Full Text] [Related]
6. The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.
Sato E; Iriyama N; Tokuhira M; Takaku T; Ishikawa M; Nakazato T; Sugimoto KJ; Fujita H; Kimura Y; Fujioka I; Asou N; Komatsu N; Kizaki M; Hatta Y; Kawaguchi T
Cancer Med; 2020 Dec; 9(23):8931-8939. PubMed ID: 33037866
[TBL] [Abstract][Full Text] [Related]
7. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
8. Chronic myeloid leukaemia: Biology and therapy.
Wang Y; Liang ZJ; Gale RP; Liao HZ; Ma J; Gong TJ; Shao YQ; Liang Y
Blood Rev; 2024 May; 65():101196. PubMed ID: 38604819
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.
Breccia M; Efficace F; Colafigli G; Scalzulli E; Di Prima A; Martelli M; Foà R
Expert Rev Hematol; 2020 Dec; 13(12):1311-1318. PubMed ID: 33205694
[No Abstract] [Full Text] [Related]
10. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP).
Iacobucci I; Storlazzi CT; Cilloni D; Lonetti A; Ottaviani E; Soverini S; Astolfi A; Chiaretti S; Vitale A; Messa F; Impera L; Baldazzi C; D'Addabbo P; Papayannidis C; Lonoce A; Colarossi S; Vignetti M; Piccaluga PP; Paolini S; Russo D; Pane F; Saglio G; Baccarani M; Foà R; Martinelli G
Blood; 2009 Sep; 114(10):2159-67. PubMed ID: 19589926
[TBL] [Abstract][Full Text] [Related]
11. Treatment-Free Remission: a New Therapeutic Goal in Chronic Myelogenous Leukemia.
Elsayed AG; Srivastava R; Jamil MO
Curr Oncol Rep; 2017 Oct; 19(12):77. PubMed ID: 28988389
[TBL] [Abstract][Full Text] [Related]
12. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
Bhalla S; Tremblay D; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):488-494. PubMed ID: 27406834
[TBL] [Abstract][Full Text] [Related]
13. Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions.
Osman AEG; Deininger MW
Blood Rev; 2021 Sep; 49():100825. PubMed ID: 33773846
[TBL] [Abstract][Full Text] [Related]
14. Deep molecular responses for treatment-free remission in chronic myeloid leukemia.
Dulucq S; Mahon FX
Cancer Med; 2016 Sep; 5(9):2398-411. PubMed ID: 27367039
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.
Ross DM; Pagani IS; Shanmuganathan N; Kok CH; Seymour JF; Mills AK; Filshie RJ; Arthur CK; Dang P; Saunders VA; Braley J; Yong AS; Yeung DT; White DL; Grigg AP; Schwarer AP; Branford S; Hughes TP;
Leukemia; 2018 Dec; 32(12):2572-2579. PubMed ID: 30315232
[TBL] [Abstract][Full Text] [Related]
16. Patient perceptions of treatment-free remission in chronic myeloid leukemia.
Villemagne Sanchez LA; O'Callaghan C; Gough K; Hall K; Kashima Y; Seymour JF; Schofield P; Ross DM
Leuk Lymphoma; 2018 Feb; 59(2):406-415. PubMed ID: 28617066
[TBL] [Abstract][Full Text] [Related]
17. ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.
Massimino M; Stella S; Tirrò E; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Tomarchio C; DI Raimondo F; Manzella L
Anticancer Res; 2020 May; 40(5):2457-2465. PubMed ID: 32366389
[TBL] [Abstract][Full Text] [Related]
18. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
Ali MA
Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
[TBL] [Abstract][Full Text] [Related]
19. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.
Chiaretti S; Vitale A; Vignetti M; Piciocchi A; Fazi P; Elia L; Falini B; Ronco F; Ferrara F; De Fabritiis P; Luppi M; La Nasa G; Tedeschi A; Califano C; Fanin R; Dore F; Mandelli F; Meloni G; Foà R
Haematologica; 2016 Dec; 101(12):1544-1552. PubMed ID: 27515250
[TBL] [Abstract][Full Text] [Related]
20. Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools.
Castagnetti F; Binotto G; Capodanno I; Billio A; Calistri E; Cavazzini F; Crugnola M; Gozzini A; Gugliotta G; Krampera M; Lucchesi A; Merli A; Miggiano MC; Minotto C; Poggiaspalla M; Salvucci M; Scappini B; Tiribelli M; Trabacchi E; Rosti G; Galimberti S; Bonifacio M
Target Oncol; 2021 Nov; 16(6):823-838. PubMed ID: 34661826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]